Golimumab

Golimumab is a human monoclonal antibody that binds tumor necrosis factor alpha (TNF-α), inhibiting its interaction with TNF receptors and reducing inflammatory activity. It is a TNF inhibitor used to treat several inflammatory conditions by modulating the immune response.

The drug is marketed in two formulations: Simponi, a subcutaneous preparation, and Simponi Aria, an intravenous infusion. In adults, approved indications include moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The subcutaneous form is given as 50 mg every four weeks, with or without methotrexate. The intravenous form is dosed at 2 mg/kg given as an infusion at weeks 0 and 4, followed by every eight weeks; this route is typically administered in a clinical setting, and coadministration with methotrexate is common for rheumatoid arthritis.

Administration and monitoring: Golimumab is administered by a healthcare professional for the IV form and by patients or caregivers for the SC form under medical guidance. Response and tolerability are monitored regularly, with attention to signs of infection or adverse reactions.

Safety and precautions: Common adverse effects include infections, injection-site reactions, and headaches. Serious risks include serious infections (including reactivation of latent tuberculosis and hepatitis B), malignancies, demyelinating diseases, and heart failure. Live vaccines should be avoided during treatment. Before starting therapy, patients should be screened for latent infections and monitored for signs of infection or reduced immune response. Immunogenicity may reduce drug effectiveness, and concurrent immunosuppressants can increase infection risk.